Efficacy of mindfulness added to treatment as usual in patients with chronic migraine and medication overuse headache: a phase-III single-blind randomized-controlled trial (the MIND-CM study)

被引:10
|
作者
Grazzi, Licia [1 ,2 ]
D'Amico, Domenico [1 ,2 ]
Guastafierro, Erika [3 ]
Demichelis, Greta [4 ]
Erbetta, Alessandra [4 ]
Fedeli, Davide [4 ]
Nigri, Anna [4 ]
Ciusani, Emilio [5 ]
Barbara, Corso [6 ]
Raggi, Alberto [3 ]
机构
[1] Fdn IRCCS Ist Neurol Carlo Besta, Neuroalgol Unit, Milan, Italy
[2] Fdn IRCCS Ist Neurol Carlo Besta, Headache Ctr, Milan, Italy
[3] Fdn IRCCS Ist Neurol Carlo Besta, Publ Hlth & Disabil Unit, Neurol, Via Celoria 11, I-20133 Milan, Italy
[4] Fdn IRCCS Ist Neurol Carlo Besta, Dept Neuroradiol, Milan, Italy
[5] Fdn IRCCS Ist Neurol Carlo Besta, Dept Diagnost & Technol, Milan, Italy
[6] CNR, Neurosci Inst, Padua, Italy
来源
JOURNAL OF HEADACHE AND PAIN | 2023年 / 24卷 / 01期
关键词
Chronic Migraine; Medication Overuse Headache; Mindfulness; Quality of Life; Disability; Migraine Prophylaxis; Cost of Illness; DISABILITY ASSESSMENT; QUESTIONNAIRE; RELIABILITY; MSQ;
D O I
10.1186/s10194-023-01630-0
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BackgroundMindfulness gained considerable attention for migraine management, but RCTs are lacking. We aimed to assess the efficacy of a six-sessions mindfulness-based treatment added to treatment as usual (TaU) in patients with Chronic Migraine (CM) and Medication Overuse Headache (MOH) on headache frequency, medication intake, quality of life, disability, depression and anxiety, cutaneous allodynia, awareness of inner states, work-related difficulties, and disease cost.MethodsIn this Phase-III single-blind RCT carried out in a specialty Italian headache center, 177 patients with CM and MOH were randomized 1:1 to either TaU (withdrawal from overused drugs, education on proper medication use and lifestyle issues, and tailored prophylaxis) or mindfulness-based intervention added to TaU (TaU + MIND). The mindfulness-based intervention consisted of six group session of mindfulness practice and 7-10 min daily self-practice. The primary endpoint was the achievement of & GE; 50% headache frequency reduction at 12 months compared to baseline, and was analyzed on an intention-to-treat principle using Pearson's Chi-Squared test. Secondary endpoints included medication intake, quality of life (QoL), disability, depression and anxiety, cutaneous allodynia, awareness of inner states, work-related difficulties, and disease cost. The secondary endpoints were analyzed using per-protocol linear mixed models.ResultsOut of the 177 participants 89 were randomized to TaU and 88 to TaU + MIND. Patients in the TaU + MIND group outperformed those in TaU for the primary endpoint (78.4% vs. 48.3%; p < 0.0001), and showed superior improvement in headache frequency, QoL and disability, headache impact, loss of productive time, medication intake, and in total, indirect and direct healthcare costs.ConclusionsA mindfulness-based treatment composed of six-week session and 7-10 min daily self-practice added on to TaU is superior to TaU alone for the treatment of patients with CM and MOH.
引用
收藏
页数:12
相关论文
共 26 条
  • [1] Efficacy of mindfulness added to treatment as usual in patients with chronic migraine and medication overuse headache: a phase-III single-blind randomized-controlled trial (the MIND-CM study)
    Licia Grazzi
    Domenico D’Amico
    Erika Guastafierro
    Greta Demichelis
    Alessandra Erbetta
    Davide Fedeli
    Anna Nigri
    Emilio Ciusani
    Corso Barbara
    Alberto Raggi
    The Journal of Headache and Pain, 24
  • [2] Efficacy of Mindfulness added to treatment as usual in patients with Chronic Migraine and Medication Overuse Headache: a randomized clinical trial, early results
    Grazzi, Licia
    D'Amico, Domenico
    Montisano, Danilo Antonio
    Guastafierro, Erika
    Del Corso, Benedetta
    Raggi, Alberto
    CEPHALALGIA, 2023, 43 (1supp) : 250 - 251
  • [3] Efficacy of mindfulness added to treatment as usual in patients with chronic migraine and medication overuse headache: a randomized clinical trial, early results
    Grazzi, L.
    Montisano, D. A.
    D'Amico, D.
    Guastafierro, E.
    Del Corso, B.
    Raggi, A.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [4] A Preliminary Analysis on the Feasibility and Short-Term Efficacy of a Phase-III RCT on Mindfulness Added to Treatment as Usual for Patients with Chronic Migraine and Medication Overuse Headache
    Grazzi, Licia
    Raggi, Alberto
    Guastafierro, Erika
    Passavanti, Marco
    Marcassoli, Alessia
    Montisano, Danilo Antonio
    D'Amico, Domenico
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (21)
  • [5] Longitudinal neurofunctional changes in medication overuse headache patients after mindfulness practice in a randomized controlled trial (the MIND-CM study)
    Fedeli, Davide
    Ciullo, Giuseppe
    Demichelis, Greta
    Carrion, Jean Paul Medina
    Bruzzone, Maria Grazia
    Ciusani, Emilio
    Erbetta, Alessandra
    Ferraro, Stefania
    Grisoli, Marina
    Guastafierro, Erika
    D'Amico, Domenico
    Raggi, Alberto
    Nigri, Anna
    Grazzi, Licia
    JOURNAL OF HEADACHE AND PAIN, 2024, 25 (01):
  • [6] Short-term efficacy of mindfulness added to treatment as usual for patients with chronic migraine and medication overuse headache
    Leonardi, Matilde
    Marcassoli, Alessia
    Sismondo, Pietro
    Curatoli, Chiara
    Lanza, Martina
    Barbadoro, Filippo
    Camarda, Giorgia
    Mazzucchelli, Alessia
    Montisano, Danilo
    D'Amico, Domenico
    Grazzi, Licia
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
  • [7] Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine A Phase 4, Randomized, Placebo-Controlled Trial
    Tepper, Stewart J.
    Dodick, David W.
    Lanteri-Minet, Michel
    Dolezil, David
    Gil-Gouveia, Raquel
    Lucas, Christian
    Piasecka-Stryczynska, Karolina
    Szabo, Gyoengyi
    Mikol, Daniel D.
    Chehrenama, Mahan
    Chou, Denise E.
    Yang, Yiping
    Lima, Gabriel Paiva da Silva
    JAMA NEUROLOGY, 2024, 81 (11) : 1140 - 1149
  • [8] Efficacy and safety of eptinezumab in patients with chronic migraine and medication-overuse headache: a randomized, double-blind, placebo-controlled study
    Shengyuan Yu
    Jiying Zhou
    Guogang Luo
    Zheman Xiao
    Anders Ettrup
    Gary Jansson
    Ioana Florea
    Kristina Ranc
    Patricia Pozo-Rosich
    BMC Neurology, 23
  • [9] Efficacy and safety of eptinezumab in patients with chronic migraine and medication-overuse headache: a randomized, double-blind, placebo-controlled study
    Yu, Shengyuan
    Zhou, Jiying
    Luo, Guogang
    Xiao, Zheman
    Ettrup, Anders
    Jansson, Gary
    Florea, Ioana
    Ranc, Kristina
    Pozo-Rosich, Patricia
    BMC NEUROLOGY, 2023, 23 (01)
  • [10] Safety and efficacy of remimazolam besylate in patients undergoing colonoscopy: A multicentre, single-blind, randomized, controlled, phase III trial
    Wang, Ximei
    Hu, Xiaolei
    Bai, Nianyue
    Li, Lie
    Zhang, Min
    Cheng, Zhigang
    Guo, Qulian
    FRONTIERS IN PHARMACOLOGY, 2022, 13